Merlino Giovanni, Gigli Gian Luigi, Valente Mariarosaria
Sleep Disorder Center, Neurology and Clinical Neurophysiology, Santa Maria della Misericordia University Hospital, Piazza Santa Maria della Misericordia, Udine, Italy.
J Nephrol. 2008 Mar-Apr;21 Suppl 13:S66-70.
Sleep disorders are common in dialysis patients. Insomnia is reported in almost 70% of the dialysed. Old age, presence of common sleep disorders, such as sleep apnea syndrome (SAS) and restless legs syndrome (RLS), comorbid clinical conditions, metabolic parameters and characteristics of dialysis, represent the main risk factors for insomnia. RLS is independently associated with uremia, affecting almost 30% of Caucasians dialysed. Pathophysiology of uremic RLS is still unclear. Although the exact pathogenetic mechanism remains unknown, the efficacy of kidney transplantation on RLS symptoms supports the involvement of renal function in this disturbance. SAS affects 30-80% of dialysis patients. The use of neurophysiological measures is necessary to diagnose SAS. This approach is not applicable in all dialysis patients; consequently, validated questionnaires might be useful to screen patients with a high risk of apnea. Risk of obstructive and central respiratory events are increased by renal failure and dialysis therapy. Excessive daytime sleepiness (EDS) is often reported by the dialysed population. Direct effects of uremic encephalopathy and of somnogenic cytokines have been suggested as the cause of EDS, in addition to the sleep disturbances that increase daytime sleepiness by impairing nocturnal sleep efficiency. Although less frequent, the presence of other sleep disturbances (such as nightmares and narcolepsy) should be carefully evaluated in the uremic population. Several sleep disturbances may potentially be treated but, if left untreated, may impair health status and increase the risk of mortality. However, literature and personal data suggest that undertreatment is common, calling to higher awareness of sleep disturbances among nephrologists.
睡眠障碍在透析患者中很常见。据报道,近70%的透析患者存在失眠问题。老年、存在常见睡眠障碍(如睡眠呼吸暂停综合征(SAS)和不宁腿综合征(RLS))、合并临床疾病、代谢参数以及透析特征,是失眠的主要危险因素。RLS与尿毒症独立相关,影响近30%接受透析的白种人。尿毒症性RLS的病理生理学仍不清楚。尽管确切的发病机制尚不清楚,但肾移植对RLS症状的疗效支持肾功能参与了这种紊乱。SAS影响30%-80%的透析患者。使用神经生理学测量方法来诊断SAS是必要的。这种方法并不适用于所有透析患者;因此,经过验证的问卷可能有助于筛查有呼吸暂停高风险的患者。肾衰竭和透析治疗会增加阻塞性和中枢性呼吸事件的风险。透析人群经常报告白天过度嗜睡(EDS)。除了睡眠障碍通过损害夜间睡眠效率增加白天嗜睡外,尿毒症性脑病和促眠细胞因子的直接作用也被认为是EDS的原因。虽然其他睡眠障碍(如梦魇和发作性睡病)较少见,但在尿毒症患者中也应仔细评估。几种睡眠障碍可能可以得到治疗,但如果不治疗,可能会损害健康状况并增加死亡风险。然而,文献和个人数据表明,治疗不足很常见,这就要求肾病学家提高对睡眠障碍的认识。